metisiline dirençli stafilokoklarda glikopeptid antibiyotiklere duyarlılık ...

47
37. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and
active efflux. Science 1994; 264: 382–8.
38. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin
Infect Dis 1997; 24(Suppl 1):567–73
39. Gür D. Temel tıptan kliniğe; beta-laktamazlar. Hacettepe Tıp Dergisi
2002;33(2):102–9.
40. Reynolds PE, Brown DFJ. Penicillin-binding protiens of betalactam-resistant
strains of Staphylococcus aureus. FEBS Lett 1985;192: 28–32.
41. Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin-and
cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 397–403.
42. Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with
beta-lactam resistance in Staphylococcus aureus. J Bacteriol 1984; 158: 513–16.
43. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus
Cassette Chromosome mec, encodes methicillin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother 2000; 44: 1549–55.
44. Jehl F, Chomarat M, Weber M, Gerard A. Antibiyotik Duyarlılık Testinden
Reçeteye. Çev: Söyletir G, Bal Ç, Gür D, Wilke Topçu A. 2. Baskı İstanbul: Bio Merieux
Yayınları Mart 2003; 78–83.
45. Tünger A, Çavuşoğlu C, Korkmaz M. Asya Mikrobiyoloji. 4. Baskı. İzmir: Asya
Tıp Kitabevi 2005; 54
46. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicilinresistant
Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
Journal of Antimicrobial Chemotherapy 1997; 40: 135–36.
47. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y,
Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus
heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670–73.
48. Bert FJ, Clarissou F, Durand D, Delefosse C, Chauvet P, Lefebvre N, et al..
Prevalence, molecular epidemiology, and clinical significance of heterogeneous
glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J. Clin.
Microbiol. 2003; 41: 5147–52.
49. Wang SSY, Ho PL, Woo PCY, and Yuen KY. Bacteremia caused by
staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 1999; 29: 760–
67.
50. CDSC. Staphylococcus aureus resistant to vancomycin-United States. MMWR
2002;51 (26): 565–7.
51. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resistance Updates
1998; 1: 135–50
52. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance
during therapy of Staphylococcus aureus endocarditis J Infect Dis 1990; 162: 103–08.
53. Brunet G, Vedal G, Dreyfus F, et al. Failure of teicoplanin therapy in two
neutropenic patients with staphylococcal septicaemia who recovered after administration of
vancomycin. Eur J Clin Microb Infect Dis 1990; 9: 145–47.
54. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplaninresistant
Staphylococcus aureus expresses a novel membrane protein and increases